Inactivation of Suv39h1 Enhances Anti-Tumor Immune Response by Increasing T Cell Activity and Decreasing T Cell Exhaustion During Anti-PD-1 Treatment
/PRNewswire/ -- Mnemo Therapeutics, a biotechnology company developing transformational immunotherapies, today announced a publication in Nature Communications...
Source: prnewswire.com